Video
Dr. Talley on “landmark study” of investigational oral treatment for complicated UTIs
Author(s):
“If approved, tebipenem could provide a new oral treatment option for patients with cUTI who have limited or no alternative oral options," says Angela Talley, MD.
Video Player is loading.
In this video, Angela Talley, MD, discusses next steps and the take-home message for the recent New England Journal of Medicine paper, “Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection,” for which she served as senior author. Talley is senior vice president of Clinical Development at Spero Therapeutics.
Related Videos
Anna Myers, CNP, discusses her approach to preventing UTIs
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
Ian Metzler, MD, on the increasing prevalence of kidney stones in women
How pre-URS tamsulosin use in pediatric patients may reduce repeat procedures
An expert discusses patient counseling in wake of FDA’s labeling changes for testosterone
Ekene Enemchukwu, MD, on vaginal estrogen for genitourinary syndrome of menopause
Expert discusses innovations in single-use ureteroscopes for stones
Naeem Bhojani, MD, discusses WATER III data on Aquablation vs enucleation for BPH
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Related Content
